China's medical products administrator approved Innovent Biologics' (HKG:1801) limertinib for a mutation of locally advanced or metastatic non-small cell lung cancer, according to a Friday filing with the Hong Kong Exchange.
The drug is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
It is indicated for the EGFR T790M mutation, which is the most common mutation and affects up to 50% of Asian patients of the disease, the filing said.
Shares rose 3% during Friday's late morning trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。